Nervous System News and Research

Latest Nervous System News and Research

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

University scientists achieve breakthrough in brain research

Chaos brews in the brains of newborns: the nerve cells are still bound only loosely to each other. Under the leadership of Academy Research Fellow Sari Lauri, a team of researchers at the University of Helsinki has been studying for years how a neural network capable of processing information effectively is created out of chaos. The team has now found a new kind of mechanism that adjusts the functional development of nerve cell contacts.

30 Sep 2009

Transient ischemic attack can trigger stroke

One out of every eight strokes is preceded by a "warning stroke," which is a transient ischemic attack (TIA) or mild stroke, according to research published in the September 29, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

29 Sep 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

Universal bilirubin screening can reduce jaundice incidence in newborns

Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.

28 Sep 2009

Research study sheds light on mechanisms of pain alteration in infancy and adolescence

Scientists at Georgia State University have uncovered the mechanisms of how pain in infancy alters how the brain processes pain in adulthood.

26 Sep 2009

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets

QRxPharma Limited,announced today a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market.

25 Sep 2009

FDA grants priority review for Cephalon's sNDA

Cephalon, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year.

25 Sep 2009

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

StemCells pushing forward its SC Proven cell culture product business

StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company’s ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company’s Cambridge, UK and Palo Alto, California locations.

23 Sep 2009

Event to address rheumatoid arthritis

26 men and women with RA from across europe honoured as they share their inspirational stories. Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA).

22 Sep 2009

UAB's researchers find early indicators for Alzheimer's disease

Inability to handle financial transactions or manage money may be an early indicator that a person with mild memory problems soon is likely to develop Alzheimer's disease, according to new research from the University of Alabama at Birmingham (UAB) Alzheimer's Disease Center, part of the Department of Neurology.

22 Sep 2009

Model-Based Design reduces the development time of FES devices

The MathWorks today announced that the Cleveland FES Center, using tools for Model-Based Design, has developed research technology that more quickly restores movement to individuals with neuromuscular disabilities.

22 Sep 2009

StemCells to take part in international networking event

StemCells, Inc. (NASDAQ:STEM) announced today its participation in the 2009 World Stem Cell Summit to be held September 21 – 23 in Baltimore, Maryland.

22 Sep 2009

Poor money management: A sign of developing Alzheimer's disease

New research finds poor money management skills may indicate that a person with mild memory problems will soon develop Alzheimer's disease. The study is published in the September 22, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

22 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

Blood vessels around the brain now converted into production/delivery systems

The blood brain barrier is generally considered an obstacle to delivering therapies from the bloodstream to the brain. However, University of Iowa researchers have discovered a way to turn the blood vessels surrounding brain cells into a production and delivery system for getting therapeutic molecules directly into brain cells.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009